EMEA-001202-PIP02-13-M04
Table of contents
Key facts
Invented name |
Cinqaero
|
Active substance |
Reslizumab
|
Therapeutic area |
Pneumology-allergology
|
Decision number |
P/0305/2020
|
PIP number |
EMEA-001202-PIP02-13-M04
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of asthma
|
Route(s) of administration |
|
Contact for public enquiries |
Teva Pharmaceuticals Europe
Tel. +44 (0)20 7540 7117 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|